Innovative Heart Health Diagnostics: An Interview with Chase Spoor of FluoroPharma 00:10:00
Mr. Spoor was previously President and CEO of AzurRx since its founding in June 2014. At AzurRx, he successfully led the Company through its Phase 2 study of MS1819-SD in chronic pancreatitis and its Phase 2 OPTION study of MS1819 in cystic fibrosis. He was previously President, Chief Executive Officer and a member of the Board of Directors of Fluoropharma Medical, Inc., was the CFO for Sunstone BioSciences, a nanotechnology firm, and a strategy consultant at Oliver Wyman working with biotechnology, pharmaceutical, medical device and health insurance companies.